Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · IEX Real-Time Price · USD
0.690
-0.042 (-5.72%)
At close: Apr 18, 2024, 4:00 PM
0.708
+0.018 (2.61%)
After-hours: Apr 18, 2024, 4:35 PM EDT
Cara Therapeutics Stock Forecast
CARA's stock price has decreased by -83.97% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Cara Therapeutics stock have an average target of 9.79, with a low estimate of 1.00 and a high estimate of 28. The average target predicts an increase of 1,318.84% from the current stock price of 0.69.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CARA stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +624.64% | Apr 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +624.64% | Mar 28, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $10 | Strong Buy | Maintains | $11 → $10 | +1,349.28% | Mar 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +624.64% | Mar 5, 2024 |
| Needham | Needham | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +624.64% | Jan 22, 2024 |
Financial Forecast
Revenue This Year
6.62M
from 20.97M
Decreased by -68.43%
Revenue Next Year
4.68M
from 6.62M
Decreased by -29.34%
EPS This Year
-1.18
from -2.19
EPS Next Year
-1.13
from -1.18
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 14.3M | 13.2M | 17.4M | 184.0M | 424.2M |
| Avg | 6.6M | 4.7M | 4.8M | 142.6M | 264.9M |
| Low | 1.3M | 294,000 | 294,000 | 53.7M | 113.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -31.6% | 99.0% | 271.7% | 3,725.3% | 197.4% |
| Avg | -68.4% | -29.3% | 2.8% | 2,865.7% | 85.7% |
| Low | -93.9% | -95.6% | -93.7% | 1,016.7% | -20.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.16 | -0.98 | -0.48 | 0.06 | 0.80 |
| Avg | -1.18 | -1.13 | -0.91 | -0.44 | 0.53 |
| Low | -1.21 | -1.31 | -1.46 | -0.91 | 0.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.